Evaluation of Tear Function among Acne Vulgaris Patients Undergoing Treatment with Isotretinoin
Journal of Ophthalmic and Optometric Sciences,
Vol. 1 No. 1 (2016),
6 October 2016
,
Page 1-6
https://doi.org/10.22037/joos.v1i1.14310
Abstract
Purpose: To evaluate the effect of Isotretinoin on tear secretion among patients with Acne Vulgaris.
Patients and Methods: In this prospective study patients candidate for isotretinoin (Accutane) therapy for two months underwent complete eye examination. The best corrected visual acuity was measures and slit lamp examination of anterior segment, evaluation of tear break-up-time and Schirmer’s test were performed. The post surgical examination carried out two months post therapy consisted of complete eye examination and evaluation of dry eye level.
Findings: Thirty nine patients entered the study. There were 5 patients complaining of eye strain before treatment, which rose to 19 patients after Isotretinoin therapy (p<0.001). The tear break up time was 13±1 seconds which decreased to 9±1 (p<0.001) after therapy and the Schirmer’s test mean reading was 22±2mm, which was reduced to 18±5 (p<0.001) after treatment. There were 4 patients with blepharitis before the treatment which rose to 19 patients after the end of Isotretinoin treatment (p<0.001).
Conclusion: Isotretinoin usage (0.5-1mg/kg for two months) impairs the tear secretion and causes dry eye and blepharitis among patients. Considering the young age of patients using this drug, some of them candidates for keratorefractive surgery, a history of Isotretinoin usage should be considered before commencing the surgery. We recommend postponing the refractive surgery among these patients until the signs of dry eye are subsided.
- Isotretinoin
- dry eye
- blepharitis
- adverse effects
How to Cite
References
Chua WC, Martin PA, Kourt G. Watery eye: A new side-effect of isotretinoin therapy. Eye (Lond). 2001; 15(Pt 1):115-6.
Cumurcu T, Sezer E, Kilic R, Bulut Y. Comparison of dose-related ocular side effects during systemic isotretinoin administration. Eur J Ophthalmol. 2009;19(2):196-200.
Egger SF, Huber-Spitzy V, Böhler K, Scholda C. Isotretinoin administration in treatment of acne vulgaris. A prospective study of the kind and extent of ocular complications. Ophthalmology. 1995;92(1):17-20.
Michel JL, Valanconny C, Gain P, Montelimard N, Tchaplyguine F, Cambazard F. Ocular manifestations of retinoids.Ann Dermatol Venereol. 1998;125(6-7):438-42.
Ellies P, Dighiero P, Legeais JM, Pouliquen YJ, Renard G. Persistent corneal opacity after oral isotretinoin therapy for acne. Cornea. 2000;19(2):238-9.
Wenham CJ, Clarke I, Shun Shin GA. Isotretinoin-related optic disc swelling. Br J Hosp Med (Lond). 2005;66(11):644-5.
Kremer I, Gaton DD, David M, Gaton E, Shapiro A. Toxic effects of systemic retinoids on meibomian glands.Ophthalmic Res. 1994;26(2):124-8.
de Queiroga IB, Antônio Vieira L, Barros Jde N, MeloDinizMde F, de Morais LC. Conjunctival impression cytology changes induced by oral isotretinoin. Cornea. 2009;28(9):1009-13.
Rismond SE, Cumurcu T, Sezer E, Kilic R, Bulut Y. Comparison of dose-related ocular side effects during systemic isotretinoin administration. Eur J Ophthalmol. 2009;19(2):196-200
Hazen PG, Carney JM, Langston RH, Meisler DM. Corneal effect of isotretinoin: possible exacerbation of corneal neovascularization in a patient with the keratitis, ichthyosis, deafness ("KID") syndrome. J Am Acad Dermatol. 1986;14(1):141-2.
- Abstract Viewed: 646 times
- PDF Downloaded: 191 times
